1. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006; 55:829–835.
2. Arias-Santiago S, Orgaz-Molina J, Castellote-Caballero L, Arrabal-Polo MÁ, García-Rodriguez S, Perandrés-López R, et al. Atheroma plaque, metabolic syndrome and inflammation in patients with psoriasis. Eur J Dermatol. 2012; 22:337–344.
![crossref](/image/icon/bnr_ref_cross.gif)
3. Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010; 20:593–598.
4. Reich K. The concept of psoriasis as a systemic inflammation: implications for disease management. J Eur Acad Dermatol Venereol. 2012; 26:Suppl 2. 3–11.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Erturan I, Köroğlu BK, Adiloğlu A, Ceyhan AM, Akkaya VB, Tamer N, et al. Evaluation of serum sCD40L and homocysteine levels with subclinical atherosclerosis indicators in patients with psoriasis: a pilot study. Int J Dermatol. 2014; 53:503–509.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Ahlehoff O, Gislason GH, Charlot M, Jørgensen CH, Lindhardsen J, Olesen JB, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011; 270:147–157.
![crossref](/image/icon/bnr_ref_cross.gif)
7. Hjuler KF, Gormsen LC, Vendelbo MH, Egeberg A, Nielsen J, Iversen L. Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. Br J Dermatol. 2017; 176:732–740.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Dowlatshahi EA, van der Voort EA, Arends LR, Nijsten T. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013; 169:266–282.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, Barker JN, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol. 2010; 130:1785–1796.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Oussalah A, Guéant JL, Peyrin-Biroulet L. Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther. 2011; 34:1173–1184.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Wang WM, Jin HZ. Homocysteine: a potential common route for cardiovascular risk and DNA methylation in psoriasis. Chin Med J (Engl). 2017; 130:1980–1986.
12. Brazzelli V, Grasso V, Fornara L, Moggio E, Gamba G, Villani S, et al. Homocysteine, vitamin B12 and folic acid levels in psoriatic patients and correlation with disease severity. Int J Immunopathol Pharmacol. 2010; 23:911–916.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Giannoni M, Consales V, Campanati A, Ganzetti G, Giuliodori K, Postacchini V, et al. Homocysteine plasma levels in psoriasis patients: our experience and review of the literature. J Eur Acad Dermatol Venereol. 2015; 29:1781–1785.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Richetta AG, Mattozzi C, Macaluso L, Cantisani C, Giancristoforo S, D'epiro S, et al. Homocysteine plasmatic status in patients with psoriasis. Eur J Dermatol. 2011; 21:621–623.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Malerba M, Gisondi P, Radaeli A, Sala R, Calzavara Pinton PG, Girolomoni G. Plasma homocysteine and folate levels in patients with chronic plaque psoriasis. Br J Dermatol. 2006; 155:1165–1169.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Vanizor Kural B, Orem A, CimXMLLink_XYZit G, Uydu HA, Yandi YE, Alver A. Plasma homocysteine and its relationships with atherothrombotic markers in psoriatic patients. Clin Chim Acta. 2003; 332:23–30.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Refsum H, Helland S, Ueland PM. Fasting plasma homocysteine as a sensitive parameter of antifolate effect: a study of psoriasis patients receiving low-dose methotrexate treatment. Clin Pharmacol Ther. 1989; 46:510–520.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Tobin AM, Hughes R, Hand EB, Leong T, Graham IM, Kirby B. Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study. Clin Exp Dermatol. 2011; 36:19–23.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Moher D, Liberati A, Tetzlaff J, Altman DG. and the PRISMA Group. Preferred reporting items for systematic reviews and meta-analysis: the PRISMA Statment. Ann Intern Med. 2009; 151:264–269.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Karabudak O, Ulusoy RE, Erikci AA, Solmazgul E, Dogan B, Harmanyeri Y. Inflammation and hypercoagulable state in adult psoriatic men. Acta Derm Venereol. 2008; 88:337–340.
21. Cakmak SK, Gül U, Kiliç C, Gönül M, Soylu S, Kiliç A. Homocysteine, vitamin B12 and folic acid levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2009; 23:300–303.
22. Dogan S, Atakan N. Is serum amyloid A protein a better indicator of inflammation in severe psoriasis? Br J Dermatol. 2010; 163:895–896.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Gisondi P, Malerba M, Malara G, Puglisi Guerra A, Sala R, Radaeli A, et al. C-reactive protein and markers for thrombophilia in patients with chronic plaque psoriasis. Int J Immunopathol Pharmacol. 2010; 23:1195–1202.
![crossref](/image/icon/bnr_ref_cross.gif)
24. Liew SC, Das-Gupta E, Wong SF, Lee N, Safdar N, Jamil A. Association of methylentetraydrofolate reductase (MTHFR) 677 C > T gene polymorphism and homocysteine levels in psoriasis vulgaris patients from Malaysia: a case-control study. Nutr J. 2012; 11:1.
![crossref](/image/icon/bnr_ref_cross.gif)
25. Romaní J, Caixàs A, Carrascosa JM, Ribera M, Rigla M, Luelmo J. Effect of narrowband ultraviolet B therapy on inflammatory markers and body fat composition in moderate to severe psoriasis. Br J Dermatol. 2012; 166:1237–1244.
![crossref](/image/icon/bnr_ref_cross.gif)
26. Akcali C, Buyukcelik B, Kirtak N, Inaloz S. Clinical and laboratory parameters associated with metabolic syndrome in Turkish patients with psoriasis. J Int Med Res. 2014; 42:386–394.
![crossref](/image/icon/bnr_ref_cross.gif)
27. Ataseven A, Kesli R, Kurtipek GS, Ozturk P. Assessment of lipocalin 2, clusterin, soluble tumor necrosis factor receptor-1, interleukin-6, homocysteine, and uric acid levels in patients with psoriasis. Dis Markers. 2014; 2014:541709.
![crossref](/image/icon/bnr_ref_cross.gif)
28. Bilgiç Ö, Altınyazar HC, Baran H, Ünlü A. Serum homocysteine, asymmetric dimethyl arginine (ADMA) and other arginine-NO pathway metabolite levels in patients with psoriasis. Arch Dermatol Res. 2015; 307:439–444.
![crossref](/image/icon/bnr_ref_cross.gif)
29. Curcó N, Barriendos N, Barahona MJ, Arteaga C, García M, Yordanov S, et al. Factors influencing cardiometabolic risk profile in patients with psoriasis. Australas J Dermatol. 2018; 59:e93–e98.
![crossref](/image/icon/bnr_ref_cross.gif)
30. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Ann Intern Med. 2013; 158:280–286.
![crossref](/image/icon/bnr_ref_cross.gif)
31. Lin X, Huang T. Oxidative stress in psoriasis and potential therapeutic use of antioxidants. Free Radic Res. 2016; 50:585–595.
![crossref](/image/icon/bnr_ref_cross.gif)
32. Mansoor MA, Bergmark C, Svardal AM, Lønning PE, Ueland PM. Redox status and protein binding of plasma homocysteine and other aminothiols in patients with early-onset peripheral vascular disease. Homocysteine and peripheral vascular disease. Arterioscler Thromb Vasc Biol. 1995; 15:232–240.
![crossref](/image/icon/bnr_ref_cross.gif)
33. Koutroubakis IE, Malliaraki N, Dimoulios PD, Karmiris K, Castanas E, Kouroumalis EA. Decreased total and corrected antioxidant capacity in patients with inflammatory bowel disease. Dig Dis Sci. 2004; 49:1433–1437.
![crossref](/image/icon/bnr_ref_cross.gif)
34. Pearce DJ, Morrison AE, Higgins KB, Crane MM, Balkrishnan R, Fleischer AB Jr, et al. The comorbid state of psoriasis patients in a university dermatology practice. J Dermatolog Treat. 2005; 16:319–323.
![crossref](/image/icon/bnr_ref_cross.gif)
35. McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch Dermatol. 1973; 107:918.
![crossref](/image/icon/bnr_ref_cross.gif)
36. Lindegård B. Diseases associated with psoriasis in a general population of 159,200 middle-aged, urban, native Swedes. Dermatologica. 1986; 172:298–304.
![crossref](/image/icon/bnr_ref_cross.gif)
37. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol. 1995; 32:982–986.
![crossref](/image/icon/bnr_ref_cross.gif)
38. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296:1735–1741.
![crossref](/image/icon/bnr_ref_cross.gif)
39. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156:271–276.
![crossref](/image/icon/bnr_ref_cross.gif)
40. Kremers HM, McEvoy MT, Dann FJ, Gabriel SE. Heart disease in psoriasis. J Am Acad Dermatol. 2007; 57:347–354.
![crossref](/image/icon/bnr_ref_cross.gif)
41. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997; 277:1775–1781.
![crossref](/image/icon/bnr_ref_cross.gif)
42. Mayer O, Filipovský J, Dolejsová M, Cífková R, Simon J, Bolek L. Mild hyperhomocysteinaemia is associated with increased aortic stiffness in general population. J Hum Hypertens. 2006; 20:267–271.
![crossref](/image/icon/bnr_ref_cross.gif)
43. Hild DH. Folate losses from the skin in exfoliative dermatitis. Arch Intern Med. 1969; 123:51–57.
![crossref](/image/icon/bnr_ref_cross.gif)
44. Fry L, Macdonald A, Almeyda J, Griffin CJ, Hoffbrand AV. The mechanism of folate deficiency in psoriasis. Br J Dermatol. 1971; 84:539–544.
![crossref](/image/icon/bnr_ref_cross.gif)
45. Touraine R, Revuz J, Zittoun J, Jarret J, Tulliez M. Study of folate in psoriasis: blood levels, intestinal absorption and cutaneous loss. Br J Dermatol. 1973; 89:335–341.
![crossref](/image/icon/bnr_ref_cross.gif)